|
About
Pharmos Corp.
Pharmos discovers and develops novel
therapeutics to treat a range of indications with a focus on specific diseases
of the nervous system including disorders of the brain-gut axis (GI/IBS),
pain/inflammation, and autoimmune disorders.
The Company's lead product, dextofisopam, is being developed as a treatment for
irritable bowel syndrome (IBS), which remains a dramatically underserved
treatment market in the U.S. and abroad. Unlike the newer IBS therapies
currently available, dextofisopam's novel non-serotonergic, brain-gut mechanism
offers a unique and innovative approach to IBS treatment.
Pharmos' core proprietary technology platform focuses on discovery and
development of synthetic cannabinoid compounds. Compounds from the Company's
extensive library of cannabinoids are being tested in preclinical studies.
Pharmos' synthetic cannabinoid library encompasses two major classes. The first
of these consists of families based on several distinct chemical scaffolds that
preferentially bind to the cannabinoid 2 (CB2) receptors.
The second class consists of dextrocannabinoids, which do not bind appreciably
to cannabinoid receptors. Members of this class act as non-competitive NMDA
antagonists and anti-oxidants, and also have the ability to block production of
inflammatory cytokines. Members of this class have potential as
anti-inflammatory and neuroprotective agents with possible applications in
neuroinflammation.
Pharmos is also working to commercialize its unique, proprietary NanoEmulsion
(NE) drug delivery system.
|
